Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—gentamicin, trimethoprim, and sulfamethoxazole—used together for their synergistic antibacterial effects. Gentamicin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Trimethoprim is a dihydrofolate reductase inhibitor that blocks folic acid synthesis in bacteria. Sulfamethoxazole is a sulfonamide antibiotic that inhibits dihydropteroate synthase, another enzyme in the folic acid pathway. When used together (trimethoprim-sulfamethoxazole as co-trimoxazole), they block sequential steps in bacterial folate synthesis, resulting in enhanced bactericidal activity. The addition of gentamicin provides further synergy against certain Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae[1][2][3][5]. This combination has been studied for use against enteric infections and other infections caused by susceptible bacteria, particularly when resistance or severe infection warrants multi-drug therapy[5]. It has veterinary applications and may be considered for severe or resistant human infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + trimethoprim-sulfamethoxazole.